This inventor holds 1 USPTO granted patent. Top assignee: Shanghai Biomedical Laboratory Co., Ltd.. Active years: 2023.
Company Filing History:
Years Active: 2023
Title: Changming Cheng: Innovator in Genetic Screening for Lung Carcinoma
Introduction
Changming Cheng is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of medical diagnostics, particularly in the early detection of lung carcinoma. His innovative work focuses on the use of genetic markers to differentiate between benign and malignant pulmonary micro-nodules.
Latest Patents
Changming Cheng holds a patent for "Genetic markers used for identifying benign and malignant pulmonary micro-nodules and the application thereof." This patent presents a group of peripheral blood gene markers that are instrumental in screening for benign and malignant pulmonary micro-nodules. The gene sequences, characterized by micronodular lung carcinoma, exhibit differential expression in the peripheral blood of patients. The invention emphasizes the use of these gene markers for early screening, showcasing high sensitivity and strong specificity. The non-invasive nature of the sampling method makes it particularly suitable for large-scale population screenings when combined with imaging techniques like CT scans.
Career Highlights
Changming Cheng is associated with Shanghai Biomedical Laboratory Co., Ltd., where he continues to advance his research and innovations. His work has the potential to revolutionize early lung cancer detection, making it more accessible and efficient for patients.
Collaborations
He has collaborated with notable colleagues, including Ruiqin Ma and Chao Yang, to further enhance the impact of his research in the medical field.
Conclusion
Changming Cheng's contributions to genetic screening for lung carcinoma represent a significant advancement in medical diagnostics. His innovative approach not only improves early detection but also enhances patient compliance through non-invasive testing methods.